- Chinese medical tech firm Cispoly secured $14M funding led by Saudi Aramco’s arm to expand its cancer detection devices.
- Cispoly’s cervical cancer screening tool is already approved in China, with ovarian and endometrial offerings in trials.
- The investment signals rising global interest in Chinese health innovation.
Cispoly Secures $14 Million Funding
Beijing-based Cispoly, a developer of gynecological tumor detection tools, has secured $14 million in its latest funding round led by Prosperity7 Ventures, the growth fund of oil giant Saudi Aramco.
The series B investment aims to support Cispoly’s R&D efforts and global expansion plans, including potential partnerships with medical institutions in Southeast Asia and Europe, founder Liu Pei said in an interview.
About the Technology
Founded in 2020, Cispoly leverages methylation detection technology to enable early diagnosis of cervical, ovarian, and endometrial cancers. Its flagship product, Ciscer, a real-time cervical cancer screening device, received regulatory approval in China earlier this year.
The startup is currently conducting clinical trials for Cisendo, its endometrial cancer detection system, and expects to begin trials soon for Cisova, an ovarian cancer screening tool.
.jpg)
Driving Innovation in Chinese Health Tech
The funding injection comes amid rising investor appetite for Chinese health tech startups.
Prosperity7 Ventures has previously backed other domestic medical device makers like exoskeleton robot maker Fourier Intelligence and heart monitor developer Jiandanxinli.
Liu said that Cispoly will use the fresh capital to speed up regulatory submissions and establish in-house manufacturing capabilities. The company also aims to explore future commercial opportunities in overseas markets.
